Evidence map›Paper›PMID 34768432›Full record

ReviewJournal of clinical medicine2021

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review.

Mathieu Gauthé, Paul Sargos, Eric Barret, Gaëlle Fromont-Hankard, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Raphaële Renard-Penna, Charles Dariane, Gaëlle Fiard and 6 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. A prospective comparative study of [European journal of nuclear medicine and molecular imaging · 2023
    Article
  4. Targeted Molecular Imaging as a Biomarker in Urologic Oncology.The Urologic clinics of North America · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 1 country.

Mathieu GauthéDepartment of Nuclear Medicine, Scintep, 38000 Grenoble, France.ORCID 0000-0002-4882-9366
Paul SargosDepartment of Radiotherapy, Institut Bergonié, 33000 Bordeaux, France.
Eric BarretDepartment of Urology, Institut Mutualiste Montsouris, 75014 Paris, France.
Gaëlle Fromont-HankardDepartment of Pathology, CHRU, 37000 Tours, France.
Jean-Baptiste BeauvalDepartment of Urology, La Croix du Sud Hospital, 31445 Quint Fonsegrives, France.
Laurent BrureauDepartment of Urology, CHU de Pointe-à-Pitre, University of Antilles, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, 97110 Pointe-à-Pitre, France.
Gilles CréhangeDepartment of Radiation Oncology Curie Institute, 75005 Paris, France.
Raphaële Renard-PennaRadiology, Pitie-Salpetriere Hospital, Sorbonne University, AP-HP, 75013 Paris, France.
Charles DarianeDepartment of Urology, Hôpital européen Georges-Pompidou, APHP, Paris-Paris University-U1151 Inserm-INEM, Necker, 75015 Paris, France.ORCID 0000-0002-9573-2938
Gaëlle FiardDepartment of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, 38000 Grenoble, France.ORCID 0000-0003-3049-5318
Romain MathieuDepartment of Urology, CHU Rennes, 35000 Rennes, France.
Guilhem RoubaudDepartment of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France.
Alain RuffionService d'urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Equipe 2-Centre d'Innovation en cancérologie de Lyon (EA 3738 CICLY)-Faculté de médecine Lyon Sud-Université Lyon 1, 69000 Lyon, France.
Morgan RouprêtGRC 5 Predictive Onco-Uro, Urology, Pitie-Salpetriere Hospital, Sorbonne University, AP-HP, 75013 Paris, France.
Guillaume PloussardDepartment of Urology, La Croix du Sud Hospital, 31445 Quint Fonsegrives, France.ORCID 0000-0002-6004-2152
On Behalf Of The Cc-Afu
Inserm · FRInstitut Bergonié · FRInstitut polytechnique de Grenoble · FRSorbonne Université · FRCentre Hospitalier Universitaire de Rennes · FRCentre Hospitalier Universitaire de Tours · FRGroupe Hospitalier Diaconesses Croix Saint-Simon · FRInstitut Curie · FRInstitute Mutualiste Montsouris · FRInstitut universitaire du cancer de Toulouse Oncopole · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans.

methodsWe performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms ("prostate cancer", "prostatic neoplasms") and ("radioligand", "radiotracer"). Included articles were clinical studies. The results were synthetized by the target type.

resultsWe included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) (

conclusionTheranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted.

Indexed as

molecular imagingnuclear medicinetherapeutics

Identifiers

PMID34768432
PMCPMC8584491
OpenAlexW3208485557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.